Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation
2023年9月22日 - 6:02AM
Dow Jones News
By Sabela Ojea
Shares of Puma Biotechnology on Thursday climbed 6.9% to $3.10
in after-hours trading after its drug alisertib received the Food
and Drug Administration's orphan drug designation to treat small
cell lung cancer.
The biopharmaceutical company said it is now working to begin
the Phase II trial of alisertib.
Orphan drug designations are granted to drugs or biologics used
for the treatment, prevention or diagnosis of a rare disease that
affects less than 200,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 21, 2023 16:47 ET (20:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Puma Biotechnology (NASDAQ:PBYI)
過去 株価チャート
から 4 2024 まで 5 2024
Puma Biotechnology (NASDAQ:PBYI)
過去 株価チャート
から 5 2023 まで 5 2024
